Current Urology Reports

, Volume 9, Issue 3, pp 197–202

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors


DOI: 10.1007/s11934-008-0035-y

Cite this article as:
Smith, M.R. Curr Urol Rep (2008) 9: 197. doi:10.1007/s11934-008-0035-y


Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Massachusetts General Hospital Cancer CenterYawkey Center 7038BostonUSA

Personalised recommendations